In a move aimed at encouraging the growth of innovation-driven industries, the Ministry of Science and Technology has proposed to set up special innovation zones that will offer a host of fiscal incentives for research and development companies in India.
The World Health Organization has given five more months to the Drugs Controller General of India to upgrade its performance to international standards. The extension of the current deadline of October-end came after a visiting WHO team found the modernisation programmes of the Indian drug regulator on track.
JWT, Crayons in race for Congress account, BJP calls for a pitch.
Sun generates 41 per cent of its annual revenues from the US market, a record of sorts among Indian drug firms. The company is bullish on its US prospects and expects 25 per cent growth in the country this year, higher than the 18-20 per cent growth projection it has given for other markets including India. The US is the world's largest market for medicines and accounts for nearly 50 per cent of the $780 billion global medicine sales.
The first petition alleges that Cipla Ltd, India's second largest pharmaceutical company, violated Roche's patent by launching a generic version of Valcyte. The second petition says Cipla violated the Swiss drug maker's trademark by launching the product in a phonetically similar name, 'Valcept'.
The group's testing lab chain SRL Ranbaxy has been renamed as Religare Super Laboratories. RanAir, its charter aviation company will be known as Religare Voyages. About 15 group companies, including joint ventures like Religare Macquarie Private Wealth, Religare Aegon and Vistaar Religare have come under the umbrella brand Religare.
Companies like Shanta Biotech, Panacea Biotec and Serum Institute of India are among the leading vaccine makers which have not been able to file any fresh application to the WHO due to this temporary de-recognition of the country's drug regulatory system. The WHO pre-qualification is essential for companies to supply vaccines to national immunisation programmes funded by the WHO or UNICEF outside the country.
Hospitals and medical research organisations that conduct clinical trials on humans may soon face surprise inspections from the regulatory authorities. The hospitals, the sponsor pharma companies and the institutional ethics committees that oversee these trials will all come under the regulator's scanner.
While stable raw materials prices have spelt relief for most FMCG companies, they are still having a tough time in defining the future pricing strategy. Most have indicated that input costs have hit their margins, while others maintained that if inflation continued unabated, there would be a further correction in prices. Many FMCG companies have either raised prices or reduced the size of their products to combat the rise in farm commodity prices and packaging costs.
Data on clinical trials of genetically-modified brinjal have been made public by the Genetic Engineering Approval Committee of the environment ministry.
The WHO feels that the practice is not only against international ethics, but also increases the risk of wrong medication. INNs are names that help to identify the chemical composition of a pharmaceutical substance without having to use long and unwieldy chemical names.
Several Indian states including Himachal Pradesh, Delhi, Goa, Madhya Pradesh and Bihar are offering their hospitals to the private sector to manage. This has elicited immediate positive reactions from private sector hospital chains - among them Fortis Healthcare, Apollo Hospitals and Wockhardt Hospitals.
Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US.
Dabur's international business stands at around Rs 380 crore (Rs 3.8 billion), out of which Nepal accounts for Rs 40 crore (Rs 400 million), while Pakistan contributes around Rs 10-12 crore (Rs 100-120 million). However, the bulk of Dabur's international business comes from the GCC (Gulf Cooperation Council) countries and Africa.
While the government expects the new urea policy to bring more investment, the fertiliser industry is less than enthused. New capacities to make urea, industry representatives say, will come up only if adequate fuel and timely payment of subsidy dues is ensured.
Medicine prices in India are set to go up by 1-2 per cent as the National Pharmaceutical Pricing Authority has decided to permit companies to factor in the rising packaging and processing costs into the retail price. The panel will notify the revised three costs -- for conversion, packaging and packing material -- shortly. The norms were finalised last week after a six-month-long analysis of the market.
The whole country broke into an impromptu celebration and by the evening, four state governments had announced cash rewards that added up to Rs 1.4 crore. Cash-rich BCCI also announced a reward of Rs 50 lakh for Bindra and Railway Minister Lalu Prasad issued him a lifetime AC first-class travel pass. Not to be left behind, budget carrier SpiceJet gave him free unlimited travel for life.
With China expected to reopen several hundred bulk drug units after the Olympics, prices of some key bulk drugs, including penicillin and paracetamol, have crashed in the Indian market.
Monetary tightening by the Reserve Bank of India to control the sharp rise in prices has checked the march of Indian consumers up the consumer electronics value chain.
The recent pullout by ICICI Venture and Citigroup Venture from a three-year-old drug discovery partnership with Dr Reddy's Laboratories points to angel investors' growing aversion to risk in pharma and biotech firms, say experts.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances